18208490. LUTEINIZING HORMONE RECEPTOR BINDING AGENTS AND LUTEINIZING HORMONE AGONISTS TO IDENTIFY, EXPAND, ABLATE AND MODIFY STEM CELLS simplified abstract (Fred Hutchinson Cancer Center)

LUTEINIZING HORMONE RECEPTOR BINDING AGENTS AND LUTEINIZING HORMONE AGONISTS TO IDENTIFY, EXPAND, ABLATE AND MODIFY STEM CELLS

Organization Name

Fred Hutchinson Cancer Center

Inventor(s)

Jarrod Dudakov of Seattle WA (US)

Marcel Van Den Brink of New York NY (US)

Enrico Velardi of New York NY (US)

Hans-Peter Kiem of Seattle WA (US)

Stefan Radtke of Seattle WA (US)

Scott James of New York NY (US)

LUTEINIZING HORMONE RECEPTOR BINDING AGENTS AND LUTEINIZING HORMONE AGONISTS TO IDENTIFY, EXPAND, ABLATE AND MODIFY STEM CELLS - A simplified explanation of the abstract

This abstract first appeared for US patent application 18208490 titled 'LUTEINIZING HORMONE RECEPTOR BINDING AGENTS AND LUTEINIZING HORMONE AGONISTS TO IDENTIFY, EXPAND, ABLATE AND MODIFY STEM CELLS

Simplified Explanation

The use of luteinizing hormone receptor (LHR) binding agents and luteinizing hormone (LH) agonists to enrich for primitive hematopoietic stem cell (pHSC) populations, to target pHSC for ablation, and/or to expand pHSC populations are described. The methods can be used to prepare therapeutic hematopoietic stem cell (HSC) populations, to prepare patients for therapeutic HSC transplants, and/or to treat malignancies, such as those associated with hyperproliferative HSC.

• LHR binding agents and LH agonists are used to target primitive hematopoietic stem cell populations.
• These methods can be utilized to prepare therapeutic HSC populations for transplantation.
• The technology can be applied to treat malignancies associated with hyperproliferative HSC.

Potential Applications

The technology can be applied in the fields of regenerative medicine, oncology, and stem cell therapy.

Problems Solved

The technology addresses the need for targeted enrichment, ablation, and expansion of primitive hematopoietic stem cell populations for therapeutic purposes.

Benefits

- Improved preparation of therapeutic hematopoietic stem cell populations - Targeted treatment of malignancies associated with hyperproliferative HSC - Potential for personalized medicine approaches in stem cell therapy

Potential Commercial Applications

- Development of novel therapies for hematopoietic disorders - Production of specialized hematopoietic stem cell populations for research and clinical use

Possible Prior Art

Prior art may include methods for enriching and expanding hematopoietic stem cell populations using different molecular targets or growth factors.

How does this technology compare to existing methods for targeting hematopoietic stem cells?

This article does not provide a direct comparison to existing methods for targeting hematopoietic stem cells. Further research or clinical trials may be needed to evaluate the efficacy and specificity of this approach.

What are the potential long-term effects of targeting primitive hematopoietic stem cells with LHR binding agents and LH agonists?

The long-term effects of targeting primitive hematopoietic stem cells with these agents are not discussed in this article. Future studies may be necessary to assess the safety and durability of this approach in clinical settings.

Original Abstract Submitted

The use of luteinizing hormone receptor (LHR) binding agents and luteinizing hormone (LH) agonists to enrich for primitive hematopoietic stem cell (pHSC) populations, to target pHSC for ablation, and/or to expand pHSC populations are described. The methods can be used to prepare therapeutic hematopoietic stem cell (HSC) populations, to prepare patients for therapeutic HSC transplants, and/or to treat malignancies, such as those associated with hyperproliferative HSC.